This immunosupportive tumor immune filtrate (increased CD8+ cells and reduced neutrophils) and corresponding reduced tumor size was only observed in the group where mice which received combination treatment with CD5-2 and anti-PD1 and not with either active drug alone. This evidence concerns the gene PDCD1 and neoplasm.